Breast cancer prevention via supplements
Marketing category for red clover and soy isoflavones, I3C, DIM, indole derivatives. Manufacturers promise reduced breast cancer risk. WHO, NCI and EMA systematic reviews do not support a quality evidence base; in patients with hormone-receptor-positive tumours phytoestrogens remain controversial.
3 drugs
Also known as: Breast cancer chemoprevention via supplements, Phytoestrogens and cancer
Marketing claims without evidence base
The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.
- DCalcium D-glucarateNot recommended · Calcium salt of D-glucaric acid (food supplement under Spanish RD 1487/2009)Calcium D-glucarate is a salt of glucaric acid, sold as a "detox" supplement and promoted for breast cancer prevention through its effect on estrogen metabolism. The supplement has not shown convincing benefit for this use: there are no quality human studies that prove a lower breast cancer risk. What does lower risk is not smoking, keeping a healthy weight, limiting alcohol, age-appropriate screening, and discussing personal risk factors with a doctor. Do not take this supplement instead of approaches with proven benefit, since that can mean missing prevention or treatment that works
- FIndole-3-carbinol (I3C)Not recommended · Plant indole derivative from cruciferous vegetables (food supplement under Spanish RD 1487/2009)Marketing promotes I3C as breast cancer protection and as liver help to clear estrogens. The NCI 2018 review found no systematic human evidence base – all recommendations rest on preclinical experiments and indirect biomarkers (the 2-OH/16α-OH ratio). The FDA issued a warning letter to BioResponse in 2008 for unsupported cancer-prevention claims and withdrew marketing authorization for DIM supplements positioned for cancer prevention. In patients with a history of hormone-receptor-positive breast cancer, I3C may interact unpredictably with tamoxifen and aromatase inhibitors – clinical data on co-use are absent. If I3C is recommended for cancer protection or to continue after a treated HR+ cancer, consider seeking a second opinion from a breast oncologist.
- FRed clover (Trifolium pratense)Not recommended · Herbal source of isoflavones (food supplement under Spanish RD 1487/2009)Manufacturers promote red clover isoflavones as phytoestrogens for breast cancer prevention. There is no supporting evidence: none of the major systematic reviews (WHO, NCI, EFSA) confirmed reduction in cancer risk. In patients with hormone-receptor-positive (HR+) breast cancer or a history of such cancer, use remains controversial – EFSA 2015 noted that isoflavones may activate ER-dependent signalling and advised avoiding long-term use in this group. SEGO 2024 does not recommend isoflavones in patients with HR+ tumours. If a doctor suggested red clover for breast cancer protection or to continue after a treated HR+ cancer, consider seeking a second opinion from a breast oncologist.
How to read tiers A–F
Evidence tiers belong to the drug-indication pair, not to the drug as a whole: the same substance can be A for one condition and F for another.
- AStrong evidence – first or second line in international guidelines
- BRecommended in selected cases
- CStudy data contradict each other
- DBenefit not proven, no documented harm
- FDocumented harm, or risk without benefit